Alleviation of pain in painful diabetic neuropathy.

Abstract:

INTRODUCTION:Painful diabetic neuropathy (PDN) is a disabling pain condition. Its pathomechanism remains unknown, but a sensitization and neuronal hyperexcitabilty have been suggested. Only symptomatic pharmacological pain management treatment is currently available. AREAS COVERED:The origin of PDN is enigmatic, and the evidence-based therapeutic guidelines therefore consist only of antidepressants and antiepileptics as first-line recommended drugs. This article relates to a MEDLINE/PubMed systematic search (2005-2015). EXPERT OPINION:The results of the meta-analysis from the aspect of the efficacy of amitriptyline, duloxetine, venlafaxine, gabapentin and pregabalin are favorable, but the placebo response rate is relatively high in patients with neuropathic pain. For personalization of the medication of PDN patients, the optimum dosing, the genotyping of the metabolizing enzymes and optimum biomarkers are needed. As concerns the future perspectives, specific sodium channel subtype inhibitors acting on peripheral nociceptive neurons or modified T-type voltage-gated calcium channel blockers may be promising targets for pharmaceutical innovations. Another attractive strategy for the treatment is based on the effects of monoclonal antibodies against nerve growth factor, sodium channels, specific receptor and cytokines. Botulinum toxin A, capsaicin patch and spinal cord stimulation therapies are the nearest future therapeutic options for the treatment of PDN patients.

authors

Tajti J,Szok D,Majláth Z,Csáti A,Petrovics-Balog A,Vécsei L

doi

10.1080/17425255.2016.1184648

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

753-64

issue

7

eissn

1742-5255

issn

1744-7607

journal_volume

12

pub_type

杂志文章,评审
  • Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?

    abstract:INTRODUCTION:Adverse drug reactions with an immune pathogenesis are a problem in the clinic and an impediment to drug development. T lymphocytes are believed to play a role in the pathogenesis; however, the nature of the drug interaction with immune receptors remains an area of debate. AREAS COVERED:This article revie...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.992780

    authors: Sullivan A,Gibson A,Park BK,Naisbitt DJ

    更新日期:2015-03-01 00:00:00

  • Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia.

    abstract:INTRODUCTION:Replacement therapy for FVIII/IX in hemophilia A/B is more than 50 years old following the discovery of cryoprecipitate by Judith Pool in 1964. On-demand therapy and prophylaxis to treat or prevent bleedings is very demanding owing to the short half-life (HL) of factor concentrates (no more than 12-14 h fo...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章

    doi:10.1080/17425255.2016.1240168

    authors: Morfini M

    更新日期:2016-11-01 00:00:00

  • Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.

    abstract:INTRODUCTION:The N-acetylation polymorphism has been the subject of comprehensive reviews describing the role of arylamine N-acetyltransferase 2 (NAT2) in the metabolism of numerous aromatic amine and hydrazine drugs. AREAS COVERED:We describe and review data that more clearly defines the effects of NAT2 haplotypes an...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章

    doi:10.1080/17425255.2021.1840551

    authors: Hein DW,Millner LM

    更新日期:2021-01-01 00:00:00

  • Tools for predicting the PK/PD of therapeutic proteins.

    abstract:INTRODUCTION:Assessments of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics are an integral part in the development of novel therapeutic agents. Compared with traditional small molecule drugs, therapeutic proteins possess many distinct PK/PD features that necessitate the application of modified or separate ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1041917

    authors: Diao L,Meibohm B

    更新日期:2015-07-01 00:00:00

  • Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation.

    abstract::Introduction: The inclusion of pharmacogenetics alongside clinical information in anticoagulant therapy offers the opportunity for a tailored approach to treatment according to individual patient characteristics. Areas covered: Literature was searched using PubMed database, focusing on pharmacogenetics of oral anticoa...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2019.1623878

    authors: Kampouraki E,Kamali F

    更新日期:2019-06-01 00:00:00

  • Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.

    abstract:INTRODUCTION:Lenalidomide is an oral immunomodulatory drug, which was recently introduced for the treatment of multiple myeloma (MM). It has been used for the treatment of newly diagnosed and relapsed MM patients, as both maintenance and preventive therapy. Available data show a progression-free survival and overall su...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.712685

    authors: Bringhen S,Gay F,Pautasso C,Cerrato C,Boccadoro M,Palumbo A

    更新日期:2012-09-01 00:00:00

  • Theragenomic knowledge management for individualised safety of drugs, chemicals, pollutants and dietary ingredients.

    abstract::Severe adverse drug reactions (ADRs) are a major problem in drug development and clinical practice and the most common cause of market withdrawals of drugs. Individualised drug safety aims at the prospective identification of single patients who carry genetic predispositions for the development of serious or fatal ADR...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.1.3.537

    authors: Gut J,Bagatto D

    更新日期:2005-10-01 00:00:00

  • Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures.

    abstract:INTRODUCTION:The goal of pharmacologic therapy with antiepileptic drugs (AEDs) is to reduce the frequency of seizures and achieve a seizure-free state with minimal side effects. However 30% of patients treated with available AEDs continue to experience uncontrolled seizures. There is still need for new AEDs with enhanc...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1360278

    authors: de Biase S,Valente M,Gigli GL,Merlino G

    更新日期:2017-09-01 00:00:00

  • Genetic variation in androgen disposition: implications in clinical medicine including testosterone abuse.

    abstract:BACKGROUND:Testosterone replacement therapy in hypogonadal men has been used for > 60 years. The use of testosterone substitution is continuously growing and is given to aging men to improve the quality of life. Because testosterone use is associated with muscle strength enhancing effects, it has become a popular drug ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425250902976862

    authors: Schulze JJ,Rane A,Ekström L

    更新日期:2009-07-01 00:00:00

  • Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs.

    abstract::Changes in mammalian diets alter the hepatic expression of CYP drug-metabolising enzymes and endobiotic oxidases. Thus, dietary constituents may significantly influence the duration of action of chemicals in tissues. Recent improvements in the mechanistic information on the regulation of constitutive and inducible exp...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.3.2.185

    authors: Murray M

    更新日期:2007-04-01 00:00:00

  • Telmisartan in the treatment of hypertension.

    abstract:BACKGROUND:Telmisartan is an orally active angiotensin II receptor antagonist prescribed once daily. OBJECTIVE:To evaluate the efficacy of telmisartan on blood pressure control, and on other end points, when given as monotherapy or in combination. METHODS:Review of published literature. RESULTS:Telmisartan produces ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.4.4.485

    authors: Rosario BH,Hendra TJ

    更新日期:2008-04-01 00:00:00

  • Pharmacokinetics considerations for gout treatments.

    abstract:INTRODUCTION:Patients with gout often have comorbid conditions such as renal failure, cardiovascular disease and metabolic syndrome. The presence and required treatment of these conditions can make the treatment of gout challenging. Knowledge of the pharmacokinetics of the available drugs for the management of gout is ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2014.915027

    authors: Richette P,Frazier A,Bardin T

    更新日期:2014-07-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation.

    abstract:INTRODUCTION:The availability of non-vitamin K antagonist oral anti-coagulants alongside vitamin K antagonists has offered a variety of options for anti-coagulation, but has also necessitated a good understanding of the pharmacological properties of each of these drugs prior to their use, to maximise the therapeutic be...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2019.1604686

    authors: Fawzy AM,Lip GYH

    更新日期:2019-05-01 00:00:00

  • Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.

    abstract:INTRODUCTION:Idiosyncratic drug-induced agranulocytosis (IDIAG) is a life-threatening adverse reaction characterized by an absolute neutrophil count < 500 cells/μl of blood. It shares many of the characteristics of other idiosyncratic drug reactions (IDRs), and this presumably reflects mechanistic similarities. AREAS ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.985649

    authors: Johnston A,Uetrecht J

    更新日期:2015-02-01 00:00:00

  • Pharmacogenetics in irritable bowel syndrome.

    abstract::Irritable bowel syndrome (IBS) is a chronic disease characterized by complex interactions between genetic predisposition and the environment. Current treatments for IBS are characterized by a highly variable response. Gene variations may result from insertions or deletions, gene rearrangements, splice variants or copy...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 社论

    doi:10.1517/17425255.2015.1048223

    authors: Acosta A,Camilleri M

    更新日期:2015-01-01 00:00:00

  • Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models.

    abstract:INTRODUCTION:Over the past decade, zebrafish have been tasked to play important roles from modeling human diseases to finding cures for them. Inadvertently, these fish now find themselves swimming along the drug development pipeline. A number of studies have been conducted to see if these small fish are up to the task ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.562197

    authors: Sukardi H,Chng HT,Chan EC,Gong Z,Lam SH

    更新日期:2011-05-01 00:00:00

  • Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.

    abstract:INTRODUCTION:Emtricitabine/tenofovir disoproxil fumarate fixed-dose combination (FTC/TDF FDC) is the co-formulation of a nucleoside and a nucleotide, respectively. After oral administration, both drugs exhibit plasma and intracellular half-lives suitable for once-daily dosing. Within the host cells, active metabolites ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.714367

    authors: Uglietti A,Zanaboni D,Gnarini M,Maserati R

    更新日期:2012-10-01 00:00:00

  • Combining stem cell-derived hepatocytes with impedance sensing to better predict human drug toxicity.

    abstract::Background: The liver plays a central role in human drug metabolism. To model drug metabolism, the major cell type of the liver, the hepatocyte, is commonly used. Hepatocytes can be derived from human and animal sources, including pluripotent stem cells. Cell-based models have shown promise in modeling human drug expo...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章

    doi:10.1080/17425255.2019.1558208

    authors: Zhou W,Graham K,Lucendo-Villarin B,Flint O,Hay DC,Bagnaninchi P

    更新日期:2019-01-01 00:00:00

  • Coffee in cancer chemoprevention: an updated review.

    abstract:INTRODUCTION:Chemoprevention of cancer refers to the use of natural or synthetic compounds to abolish or perturb a variety of steps in tumor initiation, promotion, and progression. This can be realized through different mechanisms, including activation of free radical scavenging enzymes, control of chronic inflammation...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章

    doi:10.1080/17425255.2021.1839412

    authors: Ismail T,Donati-Zeppa S,Akhtar S,Turrini E,Layla A,Sestili P,Fimognari C

    更新日期:2021-01-01 00:00:00

  • Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.

    abstract:INTRODUCTION:A major challenge in transplantation is improving long-term organ transplant and patient survival. Immunosuppressants protect the transplant organ from alloimmune reactions, but sometimes also exhibit limiting side effects. The key to improving long-term outcome following transplantation is the selection o...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.544249

    authors: Christians U,Klawitter J,Klawitter J,Brunner N,Schmitz V

    更新日期:2011-02-01 00:00:00

  • Drug-disease interactions: narrative review of aspirin in gastric ulcer.

    abstract:INTRODUCTION:Drug-disease interactions include the impact of a drug and a particular disease condition on each other. However, the current practice in addressing drug-disease interaction is unbalanced and mostly limited to how the drug worsens the disease or health condition. AREAS COVERED:Aspirin and gastric ulcer in...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2016.1201064

    authors: Nwose EU,Yee KC

    更新日期:2016-09-01 00:00:00

  • The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.

    abstract:INTRODUCTION:Boceprevir is an NS3/NS4A serine protease inhibitor that was approved for use in Hepatitis C virus (HCV) genotype 1 patients by the US Food and Drug Administration (FDA) in May 2011. The approval of this protease inhibitor marked a major paradigm shift in the treatment of HCV, as it was one of the first of...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.840290

    authors: Shankar H,Bichoupan K,Dieterich DT

    更新日期:2013-12-01 00:00:00

  • Pharmacoepigenetics: an element of personalized therapy?

    abstract:INTRODUCTION:Epigenetics is a rapidly growing field describing heritable alterations in gene expression that do not involve DNA sequence variations. Advances in epigenetics and epigenomics have influenced pharmacology, leading to the development of a new specialty, pharmacoepigenetics, the study of the epigenetic basis...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1260546

    authors: Majchrzak-Celińska A,Baer-Dubowska W

    更新日期:2017-04-01 00:00:00

  • Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:First- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, icotinib, and afatinib are the standard-of-care for first-line therapy of non-small-cell lung cancer (NSCLC) harboring activating EGFR mutations. Unfortunately, after initial ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1401064

    authors: Rossi A,Muscarella LA,Di Micco C,Carbonelli C,D'alessandro V,Notarangelo S,Palomba G,Sanpaolo G,Taurchini M,Graziano P,Maiello E

    更新日期:2017-12-01 00:00:00

  • Bioactivation of herbal constituents: simple alerts in the complex system.

    abstract:INTRODUCTION:The elucidation of the toxicological mechanisms of herbal medicines is becoming more and more important with the increasing application of herbal medicines, for treatment of various diseases and the promotion of health. Furthermore, it is widely recognized that as herbal components undergo bioactivation, t...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.586335

    authors: Fang ZZ,Zhang YY,Wang XL,Cao YF,Huo H,Yang L

    更新日期:2011-08-01 00:00:00

  • Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.

    abstract:INTRODUCTION:Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of T-cell neoplasms. Most patients with PTCL have a poor outcome with conventional therapies and are not cured without stem-cell transplantation. Pralatrexate, a novel antifolate chemotherapeutic agent, was rationally designed to impede folate m...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.595404

    authors: Foss FM

    更新日期:2011-09-01 00:00:00

  • Safety considerations for patients with epilepsy taking antiepileptic drugs alongside caffeine or other methylxanthine derivatives.

    abstract:INTRODUCTION:Antiepileptic drugs (AEDs) are widely used for the treatment of epilepsy. However, ∼ 30% of patients do not remain seizure free. It is possible that methylxanthine derivatives (e.g., caffeine and theophylline) may partially account for this outcome. AREAS COVERED:Data on the convulsive activity of methylx...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2014.920822

    authors: Chrościńska-Krawczyk M,Radzik I,Miziak B,Czuczwar SJ

    更新日期:2014-07-01 00:00:00

  • The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function.

    abstract:INTRODUCTION:Therapeutic hypothermia is being employed clinically due to its neuro-protective benefits. Both critical illness and therapeutic hypothermia significantly affect drug disposition, potentially contributing to drug-therapy and drug-disease interactions. Currently, there is limited information on the known al...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.574127

    authors: Zhou J,Poloyac SM

    更新日期:2011-07-01 00:00:00

  • Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.

    abstract::Introduction: Overactive bladder (OAB) has a heterogeneous presentation that varies between individuals and by gender. Treatment with antimuscarinic medications is standard first line pharmacotherapy for most patients with OAB. However, gender specific differences in the pharmacokinetics and pharmacodynamics of antimu...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2020.1714591

    authors: Hartigan SM,Dmochowski RR

    更新日期:2020-02-01 00:00:00

  • Deferasirox: pharmacokinetics and clinical experience.

    abstract:INTRODUCTION:Iron overload is an inevitable consequence of transfusion therapy for a variety of underlying anemias. Iron overload, without effective chelation, will lead to significant morbidity and mortality. Deferasirox (Exjade®) is an oral tridentate iron chelator used for reducing iron overload. AREAS COVERED:In a...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.640674

    authors: Galanello R,Campus S,Origa R

    更新日期:2012-01-01 00:00:00